Linus Amarikwa

Linus Amarikwa

Auto-generated profile, based on publicly available information

Linus Amarikwa

Department of Ophthalmology (L.A., N.A.H.), Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
LALinus Amarikwa
Linus Amarikwa
AMAbubakr Mohamed
Abubakr Mohamed
SKSun H Kim
Sun H Kim
AKAndrea Lora Kossler
Andrea Lora Kossler
CDChrysoula Dosiou
Chrysoula Dosiou
Context Graves orbitopathy (GO) or thyroid eye disease is a potentially sight-threatening and disfiguring autoimmune disease. Teprotumumab is a monoclonal antibody against the insulin-like growth factor-I receptor that was recently approved for GO treatment. Hyperglycemia is a recognized adverse event of teprotumumab, occurring in 10% of patients in 2 recent randomized controlled trials. Objective Our study aimed to report the incidence, severity, management, and longitudinal glycemic changes in patients treated with teprotumumab in an academic practice cohort. Methods This longitudinal, observational study included all consecutive patients treated with teprotumumab between March 2020 and May 2022 at 1 institution. Hemoglobin A1c (HbA1c) was measured every 3 months. Results Forty-two patients with baseline normoglycemia (n = 22), prediabetes (n = 10), and diabetes (n = 10) were followed for a mean of 47.5 weeks. Overall, HbA1c increased by 0.5% at 3 months. Least-squares mean changes in HbA1c at 3 months were 1.3 (P < .001), 0.7 (P = .01), and 0.1 (P = .41) in patients with diabetes, prediabetes, and normoglycemia, respectively. Twenty-two patients (52%) had hyperglycemia, which was graded as mild, moderate, and life-threatening in 55% (12/22), 41% (9/22), and 5% (1/22) of cases, respectively. Age, pre-existing diabetes, and Hispanic and Asian race/ethnicity were significant risk factors for hyperglycemia. Among patients with hyperglycemia, 36.4% (8/22) returned to baseline glycemic status at last follow-up. Conclusion While effective, teprotumumab carries a significant risk of hyperglycemia, especially in patients with diabetes. Hyperglycemia may persist after stopping teprotumumab. These findings underscore the importance of guidelines for screening and management of teprotumumab-related hyperglycemia.

31 July 2025 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
LALinus Amarikwa
Linus Amarikwa
PCPatcharaporn Chandraparnik
Patcharaporn Chandraparnik
KWKaren Wai
Karen Wai
EREhsan Rahimy
Ehsan Rahimy
BKBenyam Kinde
Benyam Kinde
AKAndrea Lora Kossler
Andrea Lora Kossler

15 January 2025 in Ophthalmology Retina
Verified
Journal Article
Closed access
MHMuhammad Hassan
Muhammad Hassan
KMKapil Mishra
Kapil Mishra
LALinus Amarikwa
Linus Amarikwa
OGOmesh P. Gupta
Omesh P. Gupta
SSSunil Srivastava
Sunil Srivastava
PMPrithvi Mruthyunjaya
Prithvi Mruthyunjaya

12 September 2025 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
LALinus Amarikwa
Linus Amarikwa
LRLynette M. Renner
Lynette M. Renner
NHNatalie A. Homer
Natalie A. Homer
KWKaren Wai
Karen Wai
CLChase A. Ludwig
Chase A. Ludwig
AKAndrea Lora Kossler
Andrea Lora Kossler

20 November 2025 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
LALinus Amarikwa
Linus Amarikwa
LRLynette M. Renner
Lynette M. Renner
KWKaren M. Wai
Karen M. Wai
NHNatalie A. Homer
Natalie A. Homer
CLChase A. Ludwig
Chase A. Ludwig
AKAndrea Lora Kossler
Andrea Lora Kossler